Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Upbeat On Ocrevus Despite Consensus Miss

COVID-19 And Competition Slows Growth

Executive Summary

Fewer patients with multiple sclerosis are switching treatment during the pandemic but despite that, and the arrival of competition from Novartis's Kesimpta, Roche insists Ocrevus growth remains strong.

You may also be interested in...



Strong Diagnostics, Biosimilar Pain Expected In Roche Q1

Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.

Novartis Wins EU Thumbs Up for MS Treatment

Kesimpta could become the first and only self-administered, targeted B-cell therapy for patients in Europe with relapsing forms of multiple sclerosis.

Novartis MS Drug Kesimpta Quick Out Of The Blocks

Kesimpta is a treatment option for multiple sclerosis patients "that doesn't need compromise, the trade-off between high efficacy and high treatment burden," Novartis neuroscience chief Norman Putzki tells Scrip.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel